---
title: Longitudinal profile of estrogen-related thrombotic biomarkers after cessation
  of combined hormonal contraceptives
date: '2023-11-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37939264/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231109170747&v=2.17.9.post6+86293ac
source: Blood
description: The persistence of risk of venous thromboembolism (VTE) due to combined
  hormonal contraceptives (CHC), after their cessation, is unknown, but is important
  to guide clinical practice. Our objective was to conduct a prospective cohort study
  to define the time until normalization of the estrogen-related thrombotic biomarkers
  after CHC cessation. We enrolled women aged 18-50 years who had decided to stop
  their CHC, excluding those with a personal history of VTE, current anticoagulation,
  a ...
disable_comments: true
---
The persistence of risk of venous thromboembolism (VTE) due to combined hormonal contraceptives (CHC), after their cessation, is unknown, but is important to guide clinical practice. Our objective was to conduct a prospective cohort study to define the time until normalization of the estrogen-related thrombotic biomarkers after CHC cessation. We enrolled women aged 18-50 years who had decided to stop their CHC, excluding those with a personal history of VTE, current anticoagulation, a ...